TIGAR and cancer: TIGAR is characterized as an F-2,6-BPase, which might be targeted with specific phosphatase inhibitors to inhibit its activity and inhibit PPP to enhance the cytotoxicity of cancer therapies as suggested with our data and reports from other groups26,58.